Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Dallah Healthcare Co's 9-Day RSI or its related term are showing as below:
SAU:4004's 9-Day RSI is ranked worse than 82.88% of 695
companies
in the Healthcare Providers & Services industry
Industry Median: 48.43
vs SAU:4004: 62.55
Dallah Healthcare Co (SAU:4004) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Dallah Healthcare Co 9-Day RSI Related Terms
SAU:4004 vs HCA, THC, DVA: 9-Day RSI Comparison
For the Medical Care Facilities subindustry, Dallah Healthcare Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's 9-Day RSI falls into.
Dallah Healthcare Co (SAU:4004) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dallah Healthcare Co (SAU:4004) has a 9-Day RSI of 62.55 as of Aug. 03, 2026. According to the industry distribution chart, Dallah Healthcare Co ranks #576 out of 695 companies in the Healthcare Providers & Services industry, placing it in the top 82.9%.
Is Dallah Healthcare Co's 9-Day RSI too high?
Dallah Healthcare Co's current 9-Day RSI is 62.55. The Healthcare Providers & Services industry median 9-Day RSI is 48.43. Dallah Healthcare Co's value of 62.55 is 29.2% above this industry median. Based on the distribution chart, Dallah Healthcare Co ranks #576 out of 695 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dallah Healthcare Co has a GF Score™ of 92/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's 9-Day RSI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dallah Healthcare Co ranks #576 out of 695 companies for 9-Day RSI. This places Dallah Healthcare Co in the lower half of its industry. The industry median 9-Day RSI is 48.43. Dallah Healthcare Co's value of 62.55 is 29.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 48.43, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current 9-Day RSI of 62.55 is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 48.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current 9-Day RSI is 62.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼207.05, compared to a current price of ﷼111.10 — trading 46.3% below its estimated fair value. The current 9-Day RSI is 62.55 and 29.2% above the Healthcare Providers & Services industry median of 48.43. Dallah Healthcare Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current 9-Day RSI is 62.55 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼111.10 is trading 46.3% below its estimated GF Value™ of ﷼207.05.
GuruFocus considers Dallah Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4004:
9-Day RSI: 62.55
GF Value™: ﷼207.05 vs. price of ﷼111.10 (46.3% below fair value)
Industry Position: 29.2% above the Healthcare Providers & Services median (#576 of 695)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
92GF Score
Get the complete analysis for SAU:4004
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
